AlbertMJ. (2020). Beyond continuationism: Climate change, economic growth, and the future of world (dis)order. Cambridge Rev Int Aff. doi.org/10.1080/09557571.2020.1825334
2.
BoregowdaU, PerisettiA, NanjappaA, GajendranM, Kutti SridharanG, and GoyalH. (2020). Addition of tocilizumab to the standard of care reduces mortality in severe COVID-19: A systematic review and meta-analysis. Front Med (Lausanne), 7, 586221.
3.
HortonR, and LoS. (2015). Planetary health: A new science for exceptional action. Lancet, 386, 1921–1922.
ÖzdemirV, and EndrenyiL. (2019). Toward panvigilance for medicinal product regulation: Clinical trial design using extremely discordant biomarkers. OMICS, 23, 131–133.
6.
ŞardaşS, EndrenyiL, GürsoyUK, et al. (2014). A call for pharmacogenovigilance and rapid falsification in the age of big data: Why not first road test your biomarker?. OMICS, 18, 663–665.
7.
SpringerS. (2020). Caring geographies: The COVID-19 interregnum and a return to mutual aid. Dialogues Hum Geogr, 10, 112–115.
8.
StoneJH, FrigaultMJ, Serling-BoydNJ, et al. (2020). Tocilizumab trial investigators. Efficacy of tocilizumab in patients hospitalized with Covid-19. N Engl J Med. DOI: 10.1056/NEJMoa2028836
9.
Von SchombergR, and ÖzdemirV. (2020). Full throttle: COVID-19 open science to build planetary public goods. OMICS, 24, 509–511.